Fig. 6From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimodModified Rodnan Skin Score (mRSS) at baseline, at weeks 4 and 8, and at follow-up in each individual patient treated with paquinimodBack to article page